Minerva Neurosciences Inc. shares rallied after the clinical-stage biotech reported study results that support its Parkinson's treatment. Shares of Minerva jumped 67% to $10 on moderate volume. The company said a compund similar to its drug MIN-301 improved Parkinson's disease symptoms in non-human primates. "We believe that MIN-301 and its analog are functionally identical and that this data provides further support for advancing MIN-301 into clinical trials for the treatment of Parkinson's disease in humans," said R�my Luthringer, president and CEO of Minerva, in a statement.
Copyright © 2015 MarketWatch, Inc.
Continue Reading Below